Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide by Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Berris van Kessel, Pascale Andre, Yannis Morel, Henk M. Lokhorst, Niels W.C.J. van de Donk, Paul W.H.I. Parren, Tuna Mutis

Get full text

Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression by Stefanie Derer, Sven Berger, Martin Schlaeth, Tanja Schneider-Merck, Katja Klausz, Stefan Lohse, Marije B. Overdijk, Michael Dechant, Christian Kellner, Iris Nagelmeier, Andreas H. Scheel, Jeroen J. Lammerts van Bueren, Jan G.J. van de Winkel, Paul W.H.I. Parren, Matthias Peipp, Thomas Valerius

Get full text

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma by Esther Drent, Richard W.J. Groen, Willy A. Noort, Maria Themeli, Jeroen J. Lammerts van Bueren, Paul W.H.I. Parren, Jürgen Kuball, Zsolt Sebestyen, Huipin Yuan, Joost de Bruijn, Niels W.C.J. van de Donk, Anton C.M. Martens, Henk M. Lokhorst, Tuna Mutis

Get full text

Systematic study of tissue factor expression in solid tumors by Johann S. deBono, Jeffrey R. Harris, Saskia M. Burm, Adriaan Vanderstichele, Mischa A. Houtkamp, Saida Aarass, Ruth Riisnaes, Ines Figueiredo, Daniel Nava Rodrigues, Rossitza Christova, Siel Olbrecht, Hans W. M. Niessen, Sigrid R. Ruuls, Danita H. Schuurhuis, Jeroen J. Lammerts van Bueren, Esther C. W. Breij, Ignace Vergote

Get full text